<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2409-2231-2019-6-2-4</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-398</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Лучевая диагностика, лучевая терапия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Radiodiagnosis, Radiotherapy</subject></subj-group></article-categories><title-group><article-title>МРТ-ПАТОМОРФОЛОГИЧЕСКИЕ ПАРАЛЛЕЛИ ПРИ ПОЛНОМ ОТВЕТЕ ОПУХОЛИ НА НЕОАДЪЮВАНТНОЕ ХИМИОЛУЧЕВОЕ ЛЕЧЕНИЕ РАКА ПРЯМОЙ КИШКИ</article-title><trans-title-group xml:lang="en"><trans-title>MRI-PATHOLOGICAL PARALLELS WITH THE COMPLETE TUMOR RESPONSE TO NEOADJUVANT CHEMORADIATION TREATMENT OF RECTAL CANCER</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3549-4499</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Березовская</surname><given-names>Т. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Berezoskaya</surname><given-names>T. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д. м.н., профессор, главный научный сотрудник клинико-морфологического отдела </p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p> MD, PhD, DSc, professor, chief researcher, clinical and morphological department</p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2168-2616</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мозеров</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mozerov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д. м.н., профессор, заведующий клинико-морфологическим отделом </p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p> MD, PhD, DSc, professor, head of clinical and morphological department</p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4524-0839</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дайнеко</surname><given-names>Я. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dayneko</surname><given-names>Ya. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> научный сотрудник</p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p>research fellow </p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5961-2958</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Невольских</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nevolskikh</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д. м.н., заместитель директора по лечебной работе </p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p> MD, PhD, DSc, deputy director for clinical care</p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8232-3422</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шавладзе</surname><given-names>З. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Shavladze</surname><given-names>Z. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p> к. м.н., заведующий отделом лучевой диагностики </p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p> MD, PhD, head of radiation diagnostics</p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7689-6032</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иванов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Ivanov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д. м.н., директор</p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p> MD, PhD, DSc, Director </p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8784-8415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каприн</surname><given-names>А. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Kaprin</surname><given-names>A. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p> академик РАН, д. м.н., профессор, заведующий кафедрой урологии и оперативной нефрологии с курсом онкоурологии</p><p>249031, Российская Федерация, Калужская область, Обнинск, ул. Королёва, д. 4</p></bio><bio xml:lang="en"><p>academician of RAS, PhD, MD, Prof.; Corr. member of the Russian Academy of Education; Honored Physician of the Russian Federation; General Director of National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Head of Department of Urology with Course of Urological Oncology, Faculty for Postgraduate Training, Peoples’ Friendship University of Russia</p><p>4 Koroleva str., Kaluga Region, Obninsk, 249036, Russian Federation</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский радиологический научный центр им. А.Ф.Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A. Tsyb Medical Radiological Research Centre — Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>26</day><month>06</month><year>2019</year></pub-date><volume>6</volume><issue>2</issue><fpage>40</fpage><lpage>50</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Березовская Т.П., Мозеров С.А., Дайнеко Я.А., Невольских А.А., Шавладзе З.Н., Иванов С.А., Каприн А.Д., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Березовская Т.П., Мозеров С.А., Дайнеко Я.А., Невольских А.А., Шавладзе З.Н., Иванов С.А., Каприн А.Д.</copyright-holder><copyright-holder xml:lang="en">Berezoskaya T.P., Mozerov S.A., Dayneko Y.A., Nevolskikh A.A., Shavladze Z.N., Ivanov S.A., Kaprin A.D.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/398">https://www.rpmj.ru/rpmj/article/view/398</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучить закономерности формирования МРТ-картины полного патоморфологического ответа (pCR) рака прямой кишки после неоадъювантной химиолучевой терапии (НХЛТ) на основе сопоставлений с патоморфологической картиной.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы. Среди 130 больных местнораспространенным раком прямой кишки, получивших комбинированное лечение с НХЛТ в клинике МРНЦ им. А. Ф. Цыба — филиал ФГБУ «НМИЦ радиологии» Министерства здравоохранения Российской Федерации в период с 2012 по 2017 гг., для включения в исследование были отобраны 13 больных, у которых, по данным патоморфологического исследования операционных препаратов, достигнут pCR. Всем больным до НХЛТ и после окончания (через 6–10 нед) лечения было проведено МРТ-исследование. Мы анализировали данные заключений МРТ из историй болезни (проспективная оценка) о степени регрессии опухоли (mrTRG) по пятибалльной шкале. У десяти из этих пациентов МРТ-исследования были доступны для повторного пересмотра (ретроспективная оценка), что позволило провести качественную оценку интенсивности сигнала в режиме Т2 по номинальной шкале, согласно которой выделяли: низкий, средний, умеренно повышенный и высокий МР-сигнал, определена локализация сигнала относительно просвета кишки с условным выделением внутреннего и наружного слоя стенки и дана характеристика наружного контура (ровный или неровный за счет гипоинтенсивных спикул). Полученные данные о локализации МР-сигнала различной интенсивности сопоставляли с данными патоморфологического описания операционных препаратов.</p></sec><sec><title>Результаты</title><p>Результаты. Проспективная МРТ-оценка рСR в 77% случаев соответствовала TRG2 и в 92% — y N0. Макроскопически рCR у всех пациентов имел вид язвенного дефекта стенки кишки, которому на Т2-ВИ в 80% случаев соответствовал умеренно повышенный МР-сигнал внутренней части стенки, обусловленный некротическими изменениями и грануляциями, и в 100% случаев — низкий МР-сигнал наружного слоя стенки кишки, обусловленный более зрелой соединительной тканью, наружный контур в 50% случаев был тяжистым за счет десмопластической реакции; отложениям извести соответствовали гипоинтенсивные включения, а «слизистым озерам» — включения с высокой интенсивностью сигнала и четкими контурами.</p></sec><sec><title>Заключение</title><p> Заключение. Особенности формирования МРТ-картины pCR обусловлены совокупностью проявлений лучевого патоморфоза, включающей деструктивные, регенераторные и воспалительные процессы в строме опухоли.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. To study the patterns of forming an MRI picture of a complete pathological morphological response (pCR) of colorectal cancer a er neoadjuvant chemoradia on therapy (NHLT) based on comparisons with the pathomorphological picture.</p></sec><sec><title> Patients and methods</title><p> Patients and methods. Among 130 patients with locally advanced colorectal cancer who received a combined treatment with NHL at A. Tsyb MRRC clinic — a Branch of HMRRC of the Ministry of Health of the Russian Federation within the period 2012–2017 thirteen patients were selected for the study, in whom pCR was achieved, according to the pathological analysis of surgical specimen. MRI was performed on all patients before the NHLT and atier the end (atier 6–10 weeks) of treatment. We analyzed the MRI ﬁ ndings from case histories (prospective assessment) on degree of tumor regression (mrTRG) using a ﬁ ve-point grading scale. Ten of these patients had MRI examinations available for re-review (retrospective assessment), which allowed for a qualitate ve assessment of the signal intensity in T2 mode on a nominal scale, according to which low, medium, moderately elevated and high MR signals were discerned; signal localization was determined relative to the intestinal lumen with conditional selection of the inner and outer layer of the wall, and the outer contour was charactezied (smooth or uneven due to hypointense spicules). The obtained data on the localization of the MR signal of varying intensity were compared with the data of the pathological description of the operating drugs.</p></sec><sec><title>Results</title><p>Results. A prospective MRI assessment of pCR in 77% of cases corresponded to TRG2 and in 92% — y N0. Macroscopically, the pCR in all patients had an appearance of an ulcerative defect of the intestinal wall, to which on T2-WI in 80% of cases corresponded to a moderately elevated MR signal from the inside of the wall, due to necroti c changes and granulations, and in 100% of cases — a low MR signal from the outer layer of the intestinal wall, caused by a more mature connective tissue, the outer contour in 50% of cases was tight due to the desmoplastic reaction; hypo-intensive inclusions corresponded to lime deposits, and “mucous lakes” — inclusions with high signal intensity and clear contours.</p><p>Conclusion The features of forming MRI picture of the pCR are due to a range of radiation pathomorphosis manifestations, including destructive, regenera ve and inﬂ ammatory processes in the tumor stroma.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>МРТ</kwd><kwd>полный ответ опухоли</kwd><kwd>неоадъювантная химиолучевая терапия</kwd><kwd>рак прямой кишки</kwd></kwd-group><kwd-group xml:lang="en"><kwd>MRI</kwd><kwd>pathologic complete response</kwd><kwd>neoadjuvant chemoradiation therapy</kwd><kwd>rectal cancer</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Старинский В. В., Петрова Г. В. (ред.) Состояние онкологической помощи населению России в 2017 году. М.: МНИОИ им. П. А. Герцена — филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Starinskij VV, Petrova GV. (editor) The state of cancer care for the popula on of Russia in 2017. Moscow: P. Hertsen Moscow Oncology Research Ins tute — Branch of the Na onal Medical Radiology Research Centre of the Ministry of Health of the Russian Federa on, 2018. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading a er preopera ve chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014 May 20;32 (15):1554–62. DOI: 10.1200/JCO.2013.54.3769</mixed-citation><mixed-citation xml:lang="en">Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading a er preopera ve chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014 May 20;32 (15):1554–62. DOI: 10.1200/JCO.2013.54.3769</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gérard JP, Chamorey E, Gourgou-Bourgade S, Benezery K, de Laroche G, Mahé MA, et al. Clinical complete response (cCR) a er neoadjuvant chemoradiotherapy and conserva ve treatment in rectal cancer. Findings from the ACCORD12/PRODIGE 2 randomized trial. Radiother Oncol. 2015 May;115 (2):246–52. DOI: 10.1016/j.radonc.2015.04.003</mixed-citation><mixed-citation xml:lang="en">Gérard JP, Chamorey E, Gourgou-Bourgade S, Benezery K, de Laroche G, Mahé MA, et al. Clinical complete response (cCR) a er neoadjuvant chemoradiotherapy and conserva ve treatment in rectal cancer. Findings from the ACCORD12/PRODIGE 2 randomized trial. Radiother Oncol. 2015 May;115 (2):246–52. DOI: 10.1016/j.radonc.2015.04.003</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, et al. Opera ve versus nonopera ve treatment for stage 0 distal rectal cancer following chemoradia on therapy: long-term results. Ann Surg. 2004 Oct;240 (4):711–7; discussion 717–8. DOI: 10.1097/01.sla.0000141194.27992.32</mixed-citation><mixed-citation xml:lang="en">Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH, et al. Opera ve versus nonopera ve treatment for stage 0 distal rectal cancer following chemoradia on therapy: long-term results. Ann Surg. 2004 Oct;240 (4):711–7; discussion 717–8. DOI: 10.1097/01.sla.0000141194.27992.32</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders a er chemoradia on for rectal cancer. J Clin Oncol. 2011 Dec 10;29 (35):4633–40. DOI: 10.1200/JCO.2011.37.7176</mixed-citation><mixed-citation xml:lang="en">Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans  PJ, Engelen SM, et al. Wait-and-see policy for clinical complete responders a er chemoradia on for rectal cancer. J Clin Oncol. 2011 Dec 10;29 (35):4633–40. DOI: 10.1200/JCO.2011.37.7176.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magne c resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011 Oct 1;29 (28):3753–60. DOI: 10.1200/JCO.2011.34.9068</mixed-citation><mixed-citation xml:lang="en">Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magne c resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011 Oct 1;29 (28):3753–60. DOI: 10.1200/JCO.2011.34.9068</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Siddiqui MR, Bhoday J, Ba ersby NJ, Chand M, West NP, Abulaﬁ AM, et al. Deﬁ ning response to radiotherapy in rectal cancer using magne c resonance imaging and histopathological scales. World J Gastroenterol. 2016 Oct 7;22 (37):8414–8434. DOI: 10.3748/wjg.v22.i37.8414</mixed-citation><mixed-citation xml:lang="en">Siddiqui MR, Bhoday J, Ba ersby NJ, Chand M, West NP, Abulaﬁ  AM, et al. Deﬁ ning response to radiotherapy in rectal cancer using magne c resonance imaging and histopathological scales. World J Gastroenterol. 2016 Oct 7;22 (37):8414–8434. DOI: 10.3748/wjg.v22.i37.8414</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мозеров С. А., Комин Ю. А., Новиков Н. Ю., Южаков В. В., Пашкин С. Б., Мозерова Е. С. Опухолевый ответ на неоадъювантную терапию при колоректальном раке. Здоровье и образование в XXI веке. 2018;20 (4):99–108</mixed-citation><mixed-citation xml:lang="en">Mozerov SA, Komin YuA, Novikov NYu, Yuzhakov VV, Pashkin SB, Mozerova ES. Tumor response to neoadjuvant therapy in colorectal cancer. Health &amp; Educa on Millemmium. 2018;20 (4):99–108. (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magne c resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011 Oct 1;29 (28):3753–60. DOI: 10.1200/JCO.2011.34.9068.</mixed-citation><mixed-citation xml:lang="en">Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magne c resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011 Oct 1;29 (28):3753–60. DOI: 10.1200/JCO.2011.34.9068.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li J, Li L, Yang L, Yuan J, Lv B, Yao Y, Xing S. Wait-and-see treatment strategies for rectal cancer pa ents with clinical complete response a erneoadjuvant chemoradiotherapy: a systema c review and meta-analysis. Oncotarget. 2016 Jul 12;7 (28):44857– 44870. DOI: 10.18632/oncotarget.8622</mixed-citation><mixed-citation xml:lang="en">Li J, Li L, Yang L, Yuan J, Lv B, Yao Y, Xing S. Wait-and-see treatment strategies for rectal cancer pa ents with clinical complete response a erneoadjuvant chemoradiotherapy: a systema c review and meta-analysis. Oncotarget. 2016 Jul 12;7 (28):44857– 44870. DOI: 10.18632/oncotarget.8622</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospec ve study using addi onal chemotherapy during the res ng period. Dis Colon Rectum. 2009 Dec;52 (12):1927–34. DOI: 10.1007/DCR.0b013e3181ba14ed</mixed-citation><mixed-citation xml:lang="en">Habr-Gama A, Perez RO, Sabbaga J, Nadalin W, São Julião GP, Gama-Rodrigues J. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospec ve study using addi onal chemotherapy during the res ng period. Dis Colon Rectum. 2009 Dec;52 (12):1927–34. DOI: 10.1007/DCR.0b013e3181ba14ed</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in pa ents with rectal cancer: opinions of Bri sh and Irish specialists. Colorectal Dis. 2010 Apr;12 (4):327–33. DOI: 10.1111/j.1463–1318.2009.01962.x</mixed-citation><mixed-citation xml:lang="en">Wynn GR, Bhasin N, Macklin CP, George ML. Complete clinical response to neoadjuvant chemoradiotherapy in pa ents with rectal cancer: opinions of Bri sh and Irish specialists. Colorectal Dis. 2010 Apr;12 (4):327–33. DOI: 10.1111/j.1463–1318.2009.01962.x</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Smith RK, Fry RD, Mahmoud NN, Paulson EC. Surveillance a er neoadjuvant therapy in advanced rectal cancer with complete clinical responsecan have comparable outcomes to total mesorectal excision. Int J Colorectal Dis. 2015 Jun;30 (6):769–74. DOI: 10.1007/s00384–015–2165–2</mixed-citation><mixed-citation xml:lang="en">Smith RK, Fry RD, Mahmoud NN, Paulson EC. Surveillance a er neoadjuvant therapy in advanced rectal cancer with complete clinical responsecan have comparable outcomes to total mesorectal excision. Int J Colorectal Dis. 2015 Jun;30 (6):769–74. DOI: 10.1007/s00384–015–2165–2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Галкин В. Н., Жаворонков Л. П., Иванов В. К., Иванов С. А., Романко Ю. С. Синтез фундаментальных и прикладных исследований — основа обеспечения высокого уровня научных результатов и внедрения их в медицинскую практику. Радиация и риск. 2017;26 (2):26–40. DOI: 10.21870/0131–3878– 2017–26–2-26–40</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Galkin VN, Zhavoronkov LP, Ivanov VK, Ivanov SA, Romanko YuS. Synthesis of basic and applied research is the basis of obtaining high-quality ﬁ ndings and transla ng them into clinical prac ce. Radia on and Risk. 2017;26 (2):26–40. DOI: 10.21870/0131–3878–2017–26–2-26–40 (In Russian).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, et al. Op mal me interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013 Jun;100 (7):933–9. DOI: 10.1002/bjs.9112</mixed-citation><mixed-citation xml:lang="en">Sloothaak DA, Geijsen DE, van Leersum NJ, Punt CJ, Buskens CJ, Bemelman WA, et al. Op mal  me interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg. 2013 Jun;100 (7):933–9. DOI: 10.1002/bjs.9112</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Du D, Su Z, Wang D, Liu W, Wei Z. Op mal interval to surgery a er neoadjuvant chemoradiotherapy in rectal cancer: a systema c review and meta-analysis. Clin Colorectal Cancer. 2018 Mar;17 (1):13–24. DOI: 10.1016/j.clcc.2017.10.012</mixed-citation><mixed-citation xml:lang="en">Du D, Su Z, Wang D, Liu W, Wei Z. Op mal interval to surgery a er neoadjuvant chemoradiotherapy in rectal cancer: a systema c review and meta-analysis. Clin Colorectal Cancer. 2018 Mar;17 (1):13–24. DOI: 10.1016/j.clcc.2017.10.012</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
